

Electrophilic Azidation of 2-Deoxy-aldono-1,5-lactones: an Alternative Route to 2-Azido-2-deoxy-aldopyranoses

François-Yves Dupradeau,^a Sen-itiroh Hakomori^{a,b} and Tatsushi Toyokuni^{*†a,c}

^a The Biomembrane Institute, 201 Elliott Avenue West, Seattle, WA 98119, USA

^b Department of Pathobiology, University of Washington, Seattle, WA 98195, USA

^c Department of Chemistry, University of Washington, Seattle, WA 98185, USA

Electrophilic azidation of tri-*O*-benzyl-2-deoxy-D-galactono-1,5-lactone **3** with triisopropylphenylsulfonyl azide, followed by selective reduction with diisobutylaluminium hydride, yielded tri-*O*-benzyl-2-azido-2-deoxy-D-galactopyranose **5** as the sole product in 80% yield, while the same sequence of reactions with the 2-deoxy-glucono-1,5-lactone derivative **8** afforded only tri-*O*-benzyl-2-azido-2-deoxy-D-mannopyranose **10** in 65% yield.

Over the past decade the carbohydrate units of glycoconjugates (glycans) have received increasing attention in both academic and industrial sectors.¹ Particularly, the recent discovery of carbohydrate-mediated cell-cell interactions associated with inflammation and cancer metastasis has initiated intensive research focused on the development of carbohydrate-based therapeutics.² Glycans often contain 2-amino-2-deoxy-aldopyranosides as their building blocks. For glycan synthesis the 2-azido-2-deoxy derivatives of mono- and di-saccharides are versatile intermediates.³ These azido sugars have been prepared by (a) azidonitration,⁴ azidohalogenation⁵ or azidophenylselenylation⁶ of *O*-protected glycals, (b) azidolysis of the 2,3-epoxide ring in 1,6-anhydro-sugars,⁷ (c) azide displacement of 2-*O*-sulfonate derivatives,⁸ or (d) the direct⁹ or stepwise¹⁰ transformation from 2-amino-2-deoxy-sugars.

Electrophilic azide transfer to enolates using arylsulfonyl azides has been studied extensively and proven to be a general approach to the asymmetric synthesis of α -amino acids.¹¹ Herein, we report our preliminary findings that electrophilic azidation is highly stereoselective for the preparation of 2-azido-2-deoxy-aldopyranoses.

The 2-deoxy-aldono-1,5-lactones **3**¹² and **8**¹³ were prepared in two steps from readily available tri-*O*-benzyl-D-glycals **1**⁵ and **6**,¹⁴ respectively (Scheme 1). Treatment of **1** and **6** in an acidic aqueous medium gave the corresponding 2-deoxy-aldopyranoses **2** and **7** without allylic rearrangement (the Ferrier reaction).¹⁵ The subsequent oxidation was effected by portionwise addition of pyridinium chlorochromate (PCC), whereas the use of Me₂SO with P₂O₅, Ac₂O or (CF₃CO)₂O was


not satisfactory. In contrast to the previous report,¹² the direct oxidation of glycals to lactones was accompanied by β -elimination leading to the formation of α,β -unsaturated lactones. Based on the ¹H NMR data ($J_{2ax,3} = J_{2eq,3} = J_{3,4} = 4.5$ Hz and NOE between H-2_{ax} and H-5), the lactone **8** seems to adopt a $B_{2,5}$ conformation rather than 4C_1 as in the case for **3** (Scheme 2).

Electrophilic azidation of **3/8** was carried out according to the procedure reported by Evans and Britton,¹¹ i.e. enolization with potassium bis(trimethylsilyl)amide (KHMDs), triazine formation with triisopropylphenylsulfonyl azide (trisyl azide)¹⁶ and quenching the reaction with AcOH. Since the azidolactones **4** and **9** decomposed slowly during work-up, the azidation was followed by selective reduction of lactone to lactol with diisobutylaluminium hydride (DIBAL-H) in the same pot, furnishing 2-azido-2-deoxy-aldopyranoses **5** and **10** in 80 and 65% overall yields, respectively. For the analysis, small amounts of **4** and **9** could be isolated by flash column chromatography on silica gel (6:1 hexane-EtOAc).


A general procedure for the one-pot reaction (**3** \rightarrow **4** \rightarrow **5** and **8** \rightarrow **9** \rightarrow **10**) is as follows: a solution of **3/8** in anhydrous THF was cooled to -90°C and a 0.5 mol dm⁻³ solution of KHMDs (1.1 equiv.) was added dropwise with vigorous stirring. After 15 min, a precooled 0.2 mol dm⁻³ solution of trisyl azide in THF (1.2 equiv., -90°C) was added dropwise. After another 2 min, AcOH (1.2 equiv.) was added and the mixture was warmed gradually to room temp. and stirred for 15 min. The mixture was again cooled to -70°C and precooled DIBAL-H (2 equiv.) was added. After 30 min, H₂O was added and the mixture was warmed to room temp. The mixture was then acidified by a few drops of 6 mol dm⁻³ HCl and stirred for 15 min. The product was extracted with CH₂Cl₂ and purified by flash column chromatography on silica gel (20:1 toluene-acetone).

The high stereochemistry of this azidation reaction, is comparable to (for the *lyxo*-series, i.e. **3**) or better than (for the *arabino*-series, i.e. **8**) those observed in the known azide additions to glycals⁴⁻⁶ mentioned above. For the azidation of **8**, the production of another diastereoisomer, the 2-azido-2-deoxy-glucopyranose derivative, was not detected. It seems that the azidation yields preferentially an equatorial azido group.[†] Therefore, the electrophilic azidation to 2-deoxy-aldono-1,5-lactones provides a highly stereoselective alternative to the existing methods for preparing 2-azido-2-deoxy-aldopyranoses.

We thank Dr Alain Veyrières (Université d'Orléans) for his kind disclosure of unpublished results regarding iodocyclization of *O*-tributylstannyl-D-galactal [Ref. 7(a)]. F.-Y. D.



Scheme 1 Reagents and conditions: i, THF-H₂O-conc. HCl (5:1:0.1), room temp. overnight, 85% **2** and 88% **7**; ii, PCC (3 \times 1 equiv. at 2 h intervals), 4 Å molecular sieves CH₂Cl₂, room temp. 5 h, 85% **3** and 90% **8**; iii, KHMDs (1.1 equiv.), THF, -90°C , 15 min; iv, trisyl azide (1.2 equiv.), 2 min; v, AcOH (1.2 equiv.), $-90^\circ\text{C} \rightarrow$ room temp.; vi, DIBAL-H (2 equiv.), THF, -70°C , 30 min; vii, H₂O, $-70^\circ\text{C} \rightarrow$ room temp. viii, 6 mol dm⁻³ HCl (a few drops), 15 min, 80% **5** from **3** and 65% **10** from **8**.



acknowledges the Conseil Régional du Centre (France) for a travel grant. We also thank Dr Steven B. Levery for assistance in NOE experiments, Ms Mary Ellen Salyan for MS analyses and Ms Jennifer Stoeck for assistance in preparation of this manuscript. This work was supported by funds from The Biomembrane Institute.

Received, 1st November 1994; Com. 4/06676F

Footnotes

† Address correspondence to this author at The Biomembrane Institute.

‡ All new compounds exhibited satisfactory spectral and high-resolution MS data.

§ *Selected physical properties of compounds.* **2**: colourless oil, 3.5:1 (α : β); ^1H NMR (500 MHz, CDCl_3) δ 5.45 (br d, 1 H, J 4.0 Hz, H-1 α), 4.13 (ddd, 1H, J 5.5, 5.5, $ca.$ 0 Hz, H-5 α), 3.98 (ddd, 1 H, J 11.0, 4.5, 3.0 Hz, H-3 α), 3.87 (br s, 1 H, H-4 α), 3.81 (br s, 1 H, H-4 β), 3.63 (dd, 1 H, J 9.5, 6.0 Hz, H-6 β), 3.58 (dd, 1 H, J 9.5, 5.5 Hz) and 3.50 (dd, 1 H, J 9.5, 5.5 Hz) ($2 \times$ H-6 α), 2.21 (ddd, 1 H, J 12.0, 11.0, 4.0 Hz, H-2ax α), 2.15 (br d, 1 H, J 12 Hz, H-2eq β) and 2.01 (ddd, 1 H, J 12.0, 4.5, $ca.$ 0 Hz, H-2eq α). HRFABMS: 457.2001 ($\text{C}_{27}\text{H}_{30}\text{NaO}_5$ [$\text{M} + \text{Na}$] $^+$, calc. 457.1991). **4**: colourless oil, $[\alpha]_D^{+63}$ (c 0.6, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 4.59 (d, 1 H, J 10.5 Hz, H-2), 4.31 (ddd, 1 H, J 9.0, 6.0, 2.0 Hz, H-5), 4.15 (br s, 1 H, H-4), 3.70 (dd, 1 H, J 10.0, 9.0 Hz) and 3.65 (dd, 1 H, J 10.0, 6.0 Hz) ($2 \times$ H-6) and 3.67 (dd, 1 H, J 10.5, 2.0 Hz, H-3). HRFABMS: 496.1839 ($\text{C}_{27}\text{H}_{27}\text{N}_3\text{NaO}_5$ [$\text{M} + \text{Na}$] $^+$, calc. 496.1848). **8**: colourless crystals, mp 79 $^\circ\text{C}$, $[\alpha]_D^{+37}$ (c 0.6, CHCl_3) {lit.¹³ mp 83 $^\circ\text{C}$, $[\alpha]_D^{+48}$ (c 1.0, EtOH)}; ^1H NMR (500 MHz, CDCl_3) δ 4.30 (ddd, 1 H, J 7.5, 4.0, 4.0 Hz, H-5), 3.94 (ddd, 1 H, J 4.5, 4.5, 4.5 Hz, H-3), 3.89 (dd, 1 H, J 7.5, 4.5 Hz, H-4), 3.73 (dd, 1 H, J 10.5, 4.0 Hz) and 3.70 (dd, 1 H, J 10.5, 4.0 Hz) ($2 \times$ H-6), 2.84 (dd, 1 H, J 15.0, 4.5 Hz, H-2ax) and 2.74 (dd, 1 H, J 15.0, 4.5 Hz, H-2eq). **9**: colourless oil, $[\alpha]_D^{+6}$ (c 0.06, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 4.33 (m, 1 H, H-5), 4.14 (d, 1 H, J 3.5 Hz, H-2), 4.05 (dd, 1 H, J 3.5, 1.5 Hz, H-3), 3.90 (dd, 1 H, J 6.0, 1.5 Hz, H-4) and 3.66 (d, 2 H, J 4.5 Hz, $2 \times$ H-6). HRFABMS: 496.1848 ($\text{C}_{27}\text{H}_{27}\text{N}_3\text{NaO}_5$ [$\text{M} + \text{Na}$] $^+$ calc. 496.1848). **10**: colourless oil, 3.5:1 (α : β); ^1H NMR (500 MHz, CDCl_3) δ 5.19 (br s, 1 H, H-1 α), 4.69 (br s, 1 H, H-1 β), 4.10 (dd, 1 H, J 9.0, 4.0 Hz, H-3 α), 3.99 (ddd, 1 H, J 9.5, 5.0, 2.5 Hz, H-5 α), 3.93 (m, 1 H, H-2 β), 3.92 (dd, 1 H, J 4.0, 2.5 Hz, H-2 α), 3.82 (dd, 1 H, J 9.5, 9.5 Hz, H-4 β), 3.78 (dd, 1 H, J 9.0, 9.0 Hz, H-4 α), 3.71 (dd, 1 H, J 9.0, 3.5 Hz, H-3 β), 3.69 (m, 2 H, $2 \times$ H-6 β) and 3.65 (m, 2 H, $2 \times$ H-6 α). HRFABMS: 498.2010 ($\text{C}_{27}\text{H}_{29}\text{N}_3\text{NaO}_5$ [$\text{M} + \text{Na}$] $^+$ calc. 498.2005).

¶ On the basis of the ^1H NMR data, the azidolactones **4** and **9** seem to exist similarly to **3** and **8** as $^4\text{C}_1$ and $B_{2,5}$ conformations, respectively. NOE between H-2 and H-5 observed in **9** implies the $B_{2,5}$ conformation.

References

- 1 Some reviews: T. M. Carlos and J. M. Harlan, *Blood*, 1994, **84**, 2068; A. Varki, *Proc. Natl. Acad. Sci. USA*, 1994, **91**, 7390; A. Varki, *Glycobiology*, 1993, **3**, 97; H. Lis and N. Sharon, *Eur. J. Biochem.*, 1993, **218**, 1.
- 2 For example, see: S. Hakomori, *Cancer Cells*, 1991, **3**, 461; K.-A. Karlsson, *TiPS*, 1991, **12**, 265; J. Hodgson, *BioTechnology*, 1991, **9**, 609; J. L. Winkelhake, *Glycoconjugate J.*, 1991, **8**, 381; B. N. N. Rao, M. Moreland and B. K. Brandley, *Med. Chem. Res.*, 1991, **1**, 1.
- 3 For example, see: H. Paulsen, *Angew. Chem., Int. Ed. Engl.*, 1990, **29**, 823; R. R. Schmidt, *Pure Appl. Chem.*, 1989, **61**, 1257.
- 4 R. U. Lemieux and R. M. Ratcliffe, *Can. J. Chem.*, 1979, **57**, 1244.
- 5 N. V. Bovin, S. É. Zurabyan and A. Ya. Khorlin, *Carbohydr. Res.*, 1981, **98**, 25.
- 6 S. Czernecki, E. Ayadi and D. Randriamandimby, *J. Chem. Soc., Chem. Commun.*, 1994, 35; F. Santoyo-González, F. G. Calvo-Flores, P. García-Mendoza, F. Hernández-Mateo, J. Isac-García and R. Robles-Díaz, *J. Org. Chem.*, 1993, **58**, 6122.
- 7 (a) D. Tailler, J.-C. Jacquinot, A.-M. Noirot and J.-M. Beau, *J. Chem. Soc., Perkin Trans. 1*, 1992, 3163; (b) T. Takamura, T. Chiba and S. Tejima, *Chem. Pharm. Bull.*, 1979, **27**, 721; (c) H. Paulsen and W. Stenzel, *Chem. Ber.*, 1978, **111**, 2334.
- 8 V. Pavliak and P. Kováč, *Carbohydr. Res.*, 1991, **210**, 333; F. Dasgupta and P. J. Garegg, *Synthesis*, 1988, 626; J. N. Vos, J. H. van Boeckel and T. Beetz, *J. Carbohydr. Chem.*, 1984, **3**, 117.
- 9 A. Vasella, C. Witzig, J.-L. Chiara and M. Martin-Lomas, *Helv. Chim. Acta*, 1991, **74**, 2073.
- 10 F. Dasgupta and P. J. Garegg, *J. Chem. Soc., Chem. Commun.*, 1989, 1640.
- 11 D. A. Evans and T. C. Britton, *J. Am. Chem. Soc.*, 1987, **109**, 6681.
- 12 P. Rollin and P. Sinaÿ, *Carbohydr. Res.*, 1981, **98**, 139.
- 13 C. Bernasconi, L. Cottier, G. Descotes and G. Rémy, *Bull. Soc. Chim. Fr.*, 1979, **5-6**, II-332.
- 14 M. Chmielewski, I. Fokt, J. Grodner, G. Grynkiewicz and W. Szeja, *J. Carbohydr. Chem.*, 1989, **8**, 735.
- 15 R. J. Ferrier and N. Prasad, *J. Chem. Soc. C*, 1969, 570.
- 16 R. E. Harmon, G. Wellman and S. K. Gupta, *J. Org. Chem.*, 1973, **38**, 11.